{"id":835,"date":"2020-12-14T06:01:08","date_gmt":"2020-12-14T14:01:08","guid":{"rendered":"https:\/\/alivamab.com\/dev\/?p=835"},"modified":"2020-12-15T11:32:02","modified_gmt":"2020-12-15T19:32:02","slug":"alivamab-discovery-services-expands-drug-discovery-platform-into-developability","status":"publish","type":"post","link":"https:\/\/alivamab.com\/dev\/alivamab-discovery-services-expands-drug-discovery-platform-into-developability\/","title":{"rendered":"AlivaMab Discovery Services Expands Drug Discovery Platform into Developability Assessment"},"content":{"rendered":"

Expansion gives AlivaMab Discovery Services the ability to streamline the transition of drug discovery programs into development <\/em><\/h2>\n

SAN DIEGO, Calif. \u2013 December 14, 2020 \u2013 AlivaMab Discovery Services,<\/a> (\"ADS\") a leader in discovery of superior antibody therapeutics, announced the expansion of its integrated platform, which now features capabilities to assess the developability of antibody therapeutics. Leveraging Alivalign software and biophysical methods, ADS will deliver assessments on therapeutic antibody specificity and manufacturability to streamline the transition from discovery to development. With this new offering, ADS will provide its partners a rapid and integrated solution for discovering and advancing fully human therapeutic antibodies towards the clinic.<\/p>\n

\"With our focus solely on therapeutic antibody discovery, every step of our workflow is designed to rapidly generate diverse panels of lead candidate antibodies that meet the target product profile, including the developability profiles required for successful drug development. By providing fully human lead antibodies and backups that are characterized for developability, including specificity, stability, expression and manufacturability, ADS provides a fully integrated approach in lead selection\" said John \u201cLippy\u201d Lippincott, PhD, Vice-President of Research of AlivaMab Discovery Services. \u201cBy expanding ADS\u2019 offerings with the addition of the Alivalign software package and the suite of biophysical methods \u2013 in combination with AlivaMab\u00ae Mouse, the only transgenic animal designed to optimize antibody drug discovery and<\/u> development \u2013 ADS can more efficiently advance our partners\u2019 projects towards the clinic.\u201d<\/p>\n

About AlivaMab Discovery Services (ADS)<\/h3>\n

AlivaMab Discovery Services is a privately held technology company with an integrated therapeutic antibody discovery platform that combines innovative technologies and deep expertise to deliver superior antibody drug candidates in rapid timelines. The combined experience of the team is demonstrated by their proven track record of having executed over 200 discovery projects yielding multiple antibody drug candidates that have entered clinical trials.\u00a0 ADS delivers diverse panels of high affinity antibody therapeutic candidates with extensive molecular and epitope diversities, functional and kinetic characterization and superior developability profiles. The integrated platform spans from the collaborative process of designing the discovery plan to the delivery of fully human therapeutic antibodies. ADS is trusted by partners ranging from global pharmaceutical companies to virtual biotechnology organizations. For more information, please visit www.alivamab.com or contact us at info@alivamab.com<\/a>.<\/p>\n

About Alivalign<\/h3>\n

Alivalign is a proprietary software that conducts in silico <\/em>analyses of antibody sequences for possible liabilities, identifies gene usage and aligns all antibodies against germ line.<\/p>\n

About AlivaMab Mouse and Ablexis, LLC<\/h3>\n

Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next generation transgenic mouse platform for human therapeutic antibody discovery. It is the only transgenic animal designed for efficient, rapid and successful antibody drug discovery and<\/u><\/em> development, incorporating fully synthetic, autonomously functioning immunoglobulin transgenes comprised of a curated repertoire of variable gene segments with a unique part-human\/part-mouse antibody composition. Ablexis has non-exclusively licensed the AlivaMab Mouse technology to several dozen companies, including the majority of the top 15 global pharmaceutical companies, additional pharmaceutical companies, multiple public and private biotechnology companies and other entities. Ablexis continues making the AlivaMab Mouse available via non-exclusive licenses. For more information, visit www.ablexis.com. For inquiries about licensing AlivaMab Mouse, contact Ablexis at info@ablexis.com<\/a>.<\/p>\n

BD Contact:
\n<\/strong>info@alivamab.com<\/a><\/p>\n

Media Contact:
\n<\/strong>Kate Proudfoot
\nkproudfoot@CGLife.com<\/a>
\n(708) 717-6570<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Expansion gives AlivaMab Discovery Services the ability to streamline the transition of drug discovery programs into development SAN DIEGO, Calif. \u2013 December 14, 2020 \u2013 AlivaMab Discovery Services, (\"ADS\") a leader in discovery of superior antibody therapeutics, announced the expansion of its integrated platform, which now features capabilities to assess the developability of antibody therapeutics. […]<\/p>\n","protected":false},"author":3,"featured_media":643,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[8],"tags":[],"_links":{"self":[{"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/posts\/835"}],"collection":[{"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/comments?post=835"}],"version-history":[{"count":8,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/posts\/835\/revisions"}],"predecessor-version":[{"id":843,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/posts\/835\/revisions\/843"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/media\/643"}],"wp:attachment":[{"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/media?parent=835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/categories?post=835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/tags?post=835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}